The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Friday, August 14, 2026

Subject of the day

TMO

Concerning the House

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

United States · www.thermofisher.com

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$42.86B+9.7%
Gross profit$2.62B+11.4%
Operating income$7.34B+12.9%
Net income$6.00B+51.6%
Cash from ops$8.67B+11.7%
Quotation

$595.89

-7.12 (-1.2%)

52w hi$638.18
52w lo$437.90
Vol1.05M
As ofAug 13
The Verdict

Hold

Our score +0.34

Short+0.21
Medium+0.47
Long+0.34

computed 2026-08-13

By the Numbers

Thermo Fisher Scientific Inc.

Healthcare · Diagnostics & Research

Market cap$220.33B
Enterprise value$261.57B
Trailing P/E32.09x
Forward P/E21.66x
EV / EBITDA22.28x
P / S (ttm)4.76x
Profit margin15.0%
Return on equity13.5%
Revenue growth+10.5%
Earnings growth+9.4%
Debt / equity80.58
Risk Metrics
Beta vs SPX0.78
Corr SPX0.42
Annual vol30.2%
Annual ret+4.2%
Sharpe0.14
Max DD-37.5%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.21
Sector+0.12
Technical+0.19
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$606.29$606.75$593.45$595.891.05M
Aug 12$599.21$604.19$595.00$603.011.53M
Aug 11$599.99$606.21$594.81$605.001.66M
Aug 10$588.53$599.69$588.53$599.691.86M
Aug 7$578.00$594.26$574.77$594.002.21M